NRDN-101

NRDN-101 is a first-in-class, disease-modifying, oral small molecule drug developed by Neurodon for the treatment of diabetes. It acts as an allosteric activator of sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), a key enzyme involved in calcium homeostasis within cells. SERCA dysfunction is implicated in both Type 1 and Type 2 diabetes due to its role in pancreatic β-cell function and insulin production. By restoring SERCA activity, NRDN-101 aims to protect pancreatic islet cells, lower blood glucose levels, increase insulin response, and attenuate β-cell death. The drug has demonstrated efficacy in preclinical studies with no observed adverse effects[1][2][3][4].